Tuesday November 10, 2015 0 comments
BOULDER -- Biodesix Inc. announced new clinical findings that show its novel investigational test, BDX008 – based on profiling serum proteins – identifies patients with advanced melanoma who are more likely to have longer progression-free and overall survival with nivolumb therapy.
“As the range of treatment options available to cancer patients continues to expand – including immunotherapy – diagnostics are increasingly important to ensure that patients receive the regimens that are most likely to prove clinical benefit,” said Dr. Richard Hockett, Biodesix’s chief medical officer.
“The results on this study are particularly exciting, as they suggest that we may be able to identify patients most likely to benefit from anti-PD-1 therapies.”
The results were presented at the 30th annual meeting of the Society for Immunotherapy of Cancer in National Harbor, Md.
Founded in 2005, Biodesix said its diagnostic tests are used for earlier disease detection, more accurate diagnosis, disease monitoring and better therapeutic guidance, leading to improved outcomes for cancer patients.